May. 5 at 8:38 PM
$ADPT
🚨🚨🚨
Adaptive Biotechnologies reported strong first quarter 2026 results driven by its Minimal Residual Disease (MRD) business.
Revenue was
$70.9 million, up 35% from the prior-year quarter, with MRD revenue of
$67.1 million, a 53% increase.
Immune Medicine revenue was
$3.8 million, down 57%, reflecting lower Genentech-related activity.
Net loss improved to
$20.0 million from
$29.8 million, and Adjusted EBITDA loss narrowed to
$2.5 million from
$12.7 million.
The company ended March 31, 2026 with
$237.2 million in cash, cash equivalents and marketable securities and raised full-year 2026 MRD revenue guidance to
$260–
$270 million, implying 22–27% annual growth.
